---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-036445"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:20:04.357861+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)

## Summary
- TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.
- Nebulized Tyvaso significantly reduced risk of clinical worsening; benefits seen across all subgroups.
- Integrated analyses of TETON-1 and TETON-2 show statistically significant treatment effects on primary and most secondary endpoints.
- Plan to submit sNDA to FDA by summer 2026 for priority review to add IPF indication for Tyvaso.
- Safety profile consistent with prior Tyvaso studies; no new safety signals observed.

## SEC filing metadata
- accession: 0001104659-26-036445
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/0001104659-26-036445-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/tm2610558d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-036445
- JSON: https://secwatch.observer/filing/0001104659-26-036445.json
- Plain text: https://secwatch.observer/filing/0001104659-26-036445.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.